SOLA Biosciences
3 known investors
SOLA Biosciences develops gene therapies for conformational diseases, using its JUMP70 platform to activate the body's protein-folding machinery to refold or remove misfolded proteins. Its lead candidate SOL-257 is a single-dose gene therapy targeting toxic TDP-43 protein aggregates in ALS.
BiotechDeep Tech
Investors · 3
Frequently asked questions
- What does SOLA Biosciences do?
- SOLA Biosciences develops gene therapies for conformational diseases, using its JUMP70 platform to activate the body's protein-folding machinery to refold or remove misfolded proteins. Its lead candidate SOL-257 is a single-dose gene therapy targeting toxic TDP-43 protein aggregates in ALS.
- Who are SOLA Biosciences's investors?
- SOLA Biosciences's investors include Eisai Innovation, Inc., MC Healthcare Ventures, UTEC.